Compare Abeona Therapeutics Inc (ABEO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Novo Nordisk A/S — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Novo Nordisk A/S trades at $48.86 (market cap $220.20B). The key difference: Novo Nordisk A/S is far larger — about 589.8× Abeona Therapeutics Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NVO | |
|---|---|---|
Market Cap | $373.32M | $220.20B |
Sector | Health | Health |
52-Week High | $7.23 | $71.70 |
52-Week Low | $4.17 | $35.29 |
Enterprise Value | $228.22M | $239.16B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Novo Nordisk (NVO) trades at $49.64, down 1.57% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with $309.1B revenue in 2025 and impressive profitability metrics including 37.2% net income margin and 71.4% ROE. Recent earnings beats and Medicare's GLP-1 coverage expansion for weight-loss drugs provide positive catalysts. Analyst consensus remains strongly bullish with 22 buy ratings versus only 3 sell recommendations.
NVO presents a compelling investment case with strong earnings growth, market leadership in GLP-1 therapies, and favorable valuation at 11.82 P/E. Key risks include intensifying competition in obesity drugs and potential pricing pressures. The stock's current technical setup near support at $49 suggests potential for rebound, supported by institutional confidence and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
